LncRNA-ATB在胆管癌中的表达及与临床病理参数和预后的关系-现代医学

LncRNA-ATB在胆管癌中的表达及与临床病理参数和预后的关系

单位：鞍钢集团总医院普外科, 辽宁大连 114002

分类号：R735.8

出版年·卷·期（页码）：2020·48·第一期（10-14）

摘要：

目的： 探讨LncRNA-ATB在胆管癌（CCA）中的表达及与临床病理参数和预后的关系。方法： 选取2009年1月至2013年12月我院收治的124例行根治性切除术的CCA患者，收集手术切除的癌组织和配对癌旁组织标本。通过实时逆转录聚合酶链反应（RT-PCR）检测CCA患者组织中lncRNA-ATB表达水平，分析CCA组织中lncRNA-ATB表达水平与临床病理参数及预后的相关性。方法： lncRNA-ATB在胆管癌组织中的相对表达量为2.84±0.52，明显高于在癌旁组织中的相对表达量1.06±0.08（P<0.05）。lncRNA-ATB表达与患者年龄、性别、分化程度无关（P>0.05），而与肿瘤大小、肿瘤浸润深度、淋巴/血管损害、淋巴结转移、UICC分期存在相关性（P<0.05）。lncRNA-ATB高表达组相比低表达组，肿瘤明显增大（P<0.05），浸润深度明显增深（P<0.05）。lncRNA-ATB高表达组的淋巴细胞浸润、血管浸润和淋巴结转移发生率明显高于低表达组（P<0.05）。高lncRNA-ATB表达组患者的无复发生存率明显低于低表达组（P<0.05）。方法： lncRNA-ATB的表达水平与CCA的恶性生物学行为呈正相关，具有肿瘤促进功能，可以作为判断CCA预后的生物标志物。

Objective: To investigate the expression of LncRNA-ATB in cholangiocarcinoma and its relationship with clinicopathological parameters and prognosis. Methods: 124 patients with CCA who underwent radical resection from January 2009 to December 2013 were selected, and the removed cancer tissues and matched adjacent tissue specimens were collected. The expression of lncRNA-ATB in CCA tissues was detected by real-time reverse transcription polymerase chain reaction (RT-PCR), and the correlation between the expression of lncRNA-ATB and clinicopathological parameters and prognosis was analyzed. Results: The relative expression of lncRNA-ATB in cholangiocarcinoma tissues was 2.84±0.52, which was significantly higher than that in adjacent tissues 1.06±0.08 (P<0.05). The expression of lncRNA-ATB was not correlated with age, gender and differentiation (P>0.05), but correlated with tumor size, depth of invasion, lymphatic/vascular lesions, lymph node metastasis and UICC staging (P<0.05). Compared with the low expression group, the tumors in the high expression group of lncRNA-ATB increased significantly (P<0.05), and the infiltration depth increased significantly (P<0.05) as well. The incidence of lymphocyte infiltration, vascular infiltration and lymph node metastasis in the high expression group of lncRNA-ATB were significantly higher than those in the low expression group.The recurrence-free survival rate in the high expression group of lncRNA-ATB was significantly lower than that in the low expression group (P<0.05). Conclusion: The expression level of lncRNA-ATB is positively correlated with the malignant biological behavior of CCA, which can be used as a biomarker to judge the prognosis of CCA.

参考文献：

[1] 晏益核,黄玉斌,蔡小勇.肝门部胆管癌的外科治疗现状[J].中国普通外科杂志,2017,26(2):246-251.
[2] LUMACHI F,CHIARA G,TOZZOLI R,et al.P-035 simultaneous carcinoembryonic antigen (CEA),carcinoma antigen 19-9(CA 19-9) and 125(CA-125) measurement in patients with gastric cancer (stage IA-IB):a case-control study[J].Annals of Oncology,2016,27(suppl_2):ii10-ii11.
[3] XUE X,YANG Y A,ZHANG A,et al.LncRNAHOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer[J].Oncogene,2016,35(21):2746-2755.
[4] ENGREITZ J M,HAINES J E,PEREZ E M,et al.Local regulation of gene expression by lncRNA promoters,transcription and splicing[J].Nature,2016,539(7629):452-455.
[5] ARUN G,DIERMEIER S,AKERMAN M,et al.Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss[J].Genes and Development,2016,30(1):34-51.
[6] MATOUK I J,HALLE D,RAVEH E,et al.The role of the oncofetal H19 lncRNA in tumor metastasis:orchestrating the EMT-MET decision[J].Oncotarget,2016,7(4):3748-3765.
[7] HU X,BAO J,WANG Z,et al.The plasma lncRNA acting as fingerprint in non-small-cell lung cancer[J].Tumor Biology,2016,37(3):3497-3504.
[8] 项灿宏,童翾.肝门部胆管癌外科治疗的进展与争议[J].中国普通外科杂志,2018,27(2):137-142.
[9] 罗洁.肝门部胆管癌手术后长期随访[D].福州:福建医科大学,2016.
[10] DICKSON I.Hepatocellular carcinoma:a role for lncRNA in liver cancer[J].Nature Reviews Gastroenterology and Hepatology,2016,13(3):122-123.
[11] HUANG R,WANG X,ZHANG W,et al.Down-Regulation of LncRNA DGCR5 correlates with poor prognosis in hepatocellular carcinoma[J].Cellular Physiology and Biochemistry,2016,40(3-4):707-715.
[12] SUN M,NIE F,WANG Y,et al.LncRNA HOXA11-AS promotes proliferation and invasion of gastric cancer by scaffolding the chromatin modification factors PRC2,LSD1,and DNMT1[J].Cancer Research,2016,76(21):6299-6310.
[13] 韩晓辉.与肝纤维化发病相关的长链非编码RNAs的筛选鉴定及功能的初步研究[D].天津:天津医科大学,2017.
[14] ZHENG B,JEONG S,ZHU Y,et al.miRNA and lncRNA as biomarkers in cholangiocarcinoma (CCA)[J].Oncotarget,2017,8(59):100819-100830.
[15] CHEN F,LI Y,FENG Y,et al.Evaluation of antimetastatic effect of lncRNA-ATB siRNA delivered using ultrasound-targeted microbubble destruction[J].Dna and Cell Biology,2016,35(8):393-397.
[16] SUFARU I G,BEIKIRCHER G,WEINHAEUSEL A,et al.Inhibitors of DNA methylation support TGF-β1-induced IL11 expression in gingival fibroblasts[J].Journal of Periodontal and Implant Science,2017,47(2):66-76.
[17] PENG L,YUAN X,JIANG B,et al.LncRNAs:key players and novel insights into cervical cancer[J].Tumor Biology,2016,37(3):2779-2788.
[18] LUO S,LU J Y,LIU L,et al.Divergent lncRNAs regulate gene expression and lineage differentiation in pluripotent cells[J].Cell Stem Cell,2016,18(5):637-652.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录